Trial Profile
An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Axitinib; Bevacizumab; Capecitabine; Pazopanib
- Indications Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 12 Apr 2019 According to a TRACON Pharmaceuticals media release, based on a review of TAPPAS trial data, the Independent Data Monitoring Committee (IDMC) recommended to terminate TAPPAS trial. The company also decided to terminate further enrollment in company sponsored trials of TRC105 in oncology.
- 12 Apr 2019 Status changed from recruiting to discontinued.
- 05 Feb 2015 New trial record